Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00991562 · ClinicalTrials.gov registry record · Phase 1

IMGN901 in Combination With Lenalidomide and Dexamethasone

A Phase 1 study, sponsored by ImmunoGen.

Completed
Registry status
Phase 1
Development phase
50
Enrollment target

NCT00991562 is a Phase 1 study that has completed, run by ImmunoGen. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00991562, a Phase 1 study, has completed, sponsored by ImmunoGen.

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target

Study Summary

The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.

Interventions

  • DRUG IMGN901

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2009-12
Est. Completion 2014-10
Phase Phase 1

Sponsor

ImmunoGen

15 total trials

What the Registry Record Tells You About NCT00991562

The ClinicalTrials.gov registry entry for NCT00991562 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which IMGN901 is the first listed.

NCT00991562 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00991562 about?

NCT00991562 is a clinical study titled "IMGN901 in Combination With Lenalidomide and Dexamethasone". The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.

What is the current status of trial NCT00991562?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2009-12. Estimated completion is 2014-10.

What interventions are being tested in trial NCT00991562?

The interventions under investigation include: IMGN901 (DRUG).

Who is sponsoring clinical trial NCT00991562?

This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.